Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00128921 · ClinicalTrials.gov registry record · Phase 2
Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma
A Phase 2 study, sponsored by University of Arkansas.
- Terminated
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
NCT00128921 is a Phase 2 study that was terminated before completion, run by University of Arkansas. The registered enrollment target is 18 participants.
The verdict
NCT00128921, a Phase 2 study, was terminated before completion, sponsored by University of Arkansas.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
Study Summary
Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma for patients who have received at least one prior therapy. Velcade is a unique compound developed by scientists at Millennium Pharmaceuticals, Inc. Velcade enters cells and affects the way they divide. Cancer cells are particularly sensitive. Velcade interferes with the enzyme "proteasome" which is responsible for allowing cells to divide. When cancer cells cannot divide, they die. Velcade falls into the class of drugs known as "proteasome inhibitors."
Interventions
- DRUG VELCADE™
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-04 |
| Est. Completion | 2008-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00128921
The ClinicalTrials.gov registry entry for NCT00128921 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VELCADE™ is the first listed.
NCT00128921 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00128921 about?
NCT00128921 is a clinical study titled "Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma". Velcade (bortezomib, PS-341) has recently been approved by the Food and Drug Administration (FDA) for the treatment of multiple myeloma for patients who have received at least one prior therapy. Velcade is a unique compound developed by scientists at Millennium Pharmaceuticals, Inc. Velcade enters c...
What is the current status of trial NCT00128921?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2006-04. Estimated completion is 2008-02.
What interventions are being tested in trial NCT00128921?
The interventions under investigation include: VELCADE™ (DRUG).
Who is sponsoring clinical trial NCT00128921?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.